chevron_leftBack
As of 24 April 2025, Almirall, S.A. has a market cap of $2.29B USD, ranking #4955 globally and #42 in Spain. It ranks #444 in the Healthcare sector, and #90 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$2.29BUSD
2.01B EUR
Enterprise Value
$2.3BUSD
2.03B EUR
Revenue (TTM)
$1.13BUSD
990.63M EUR
EBITDA (TTM)
$196.32MUSD
173.24M EUR
Net Income (TTM)
$11.55MUSD
10.15M EUR
EBITDA Margin
17%
Profit Margin
1%
PE Ratio
196.5
Company Profile
Country (HQ)
Sector
Healthcare
CEO
Carlos Gallardo Piqué
open_in_new
Employees
2,026
Founded
1943
Website
almirall.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0.6% | -0.1% | -8.8% | 11% | 1.3% | 14% |
Upcoming Earnings
Earnings Date
Mon, May 12
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ALM
Almirall SA
ISIN: ES0157097017
Shares Out.:
Shares Outstanding:
213.469M1
Shares Float:
74.258M2
|
9.49 EUR |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Almirall, S.A.
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, nervous, and respiratory system; dermatologicals; genito urinary system and sex hormones; immunostimulants; metabolism; and systematic hormonal preparations. It has a multi-target partnership with Etherna to research and develop mRNA-based therapies for medical dermatology. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
